A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

MLA

Abramson V, et al. A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of Taselisib (GDC-0032) in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative, Locally Advanced, or Metastatic Breast Cancer. Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....e1ef52eb712a0bc75c21f04457f43565&authtype=sso&custid=ns315887.

APA

Abramson V, Oliveira M, Cervantes A, Wildiers H, Patel M, Bauer T, Bedard P, Becerra C, Richey S, Wei M, Reyner E, Bond J, Cui N, Wilson T, Moore H, Saura C, & Krop I. (2019). A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.

Chicago

Abramson V, Oliveira M, Cervantes A, Wildiers H, Patel M, Bauer T, Bedard P, et al. 2019. “A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of Taselisib (GDC-0032) in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative, Locally Advanced, or Metastatic Breast Cancer,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....e1ef52eb712a0bc75c21f04457f43565&authtype=sso&custid=ns315887.